<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(14)</volume><submitter>Yang HS</submitter><pubmed_abstract>&lt;b>Background&lt;/b>: Patients with "driver gene-negative" LUAD lack effective targeted therapies. This study aimed to elucidate the role of the glycolysis pathway in driver gene-negative LUAD to identify key genes and potential therapeutic targets. &lt;b>Methods&lt;/b>: Bulk RNA sequencing data from 49 patients with driver gene-negative LUAD were analyzed. The driver gene-negative status of patients was confirmed by immunoblotting. Gene set enrichment analysis (GSEA) was conducted on six hallmark pathways related to glycolysis. Additionally, key genes were identified and a risk score model was constructed. Finally, single-cell RNA sequencing data were processed using the Seurat package for data cleaning, dimensionality reduction clustering, and cell type identification. &lt;b>Results&lt;/b>: GSEA analys</pubmed_abstract><journal>Journal of Cancer</journal><pagination>4233-4244</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12595263</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Exploring the Glycolytic Mechanisms in "Driver Gene-Negative" Lung Adenocarcinoma (LUAD): A Single-Cell RNA Sequencing Approach to Identify the MIF-HIF-1α Axis.</pubmed_title><pmcid>PMC12595263</pmcid><pubmed_authors>Chen Q</pubmed_authors><pubmed_authors>Liang CY</pubmed_authors><pubmed_authors>Yang HS</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Han Y</pubmed_authors><pubmed_authors>Zhu W</pubmed_authors><pubmed_authors>Yu QD</pubmed_authors><pubmed_authors>Li YH</pubmed_authors><pubmed_authors>Luo HH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Exploring the Glycolytic Mechanisms in "Driver Gene-Negative" Lung Adenocarcinoma (LUAD): A Single-Cell RNA Sequencing Approach to Identify the MIF-HIF-1α Axis.</name><description>&lt;b>Background&lt;/b>: Patients with "driver gene-negative" LUAD lack effective targeted therapies. This study aimed to elucidate the role of the glycolysis pathway in driver gene-negative LUAD to identify key genes and potential therapeutic targets. &lt;b>Methods&lt;/b>: Bulk RNA sequencing data from 49 patients with driver gene-negative LUAD were analyzed. The driver gene-negative status of patients was confirmed by immunoblotting. Gene set enrichment analysis (GSEA) was conducted on six hallmark pathways related to glycolysis. Additionally, key genes were identified and a risk score model was constructed. Finally, single-cell RNA sequencing data were processed using the Seurat package for data cleaning, dimensionality reduction clustering, and cell type identification. &lt;b>Results&lt;/b>: GSEA analys</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-06-05T12:45:44.384Z</modification><creation>2026-05-17T03:07:45.066Z</creation></dates><accession>S-EPMC12595263</accession><cross_references><pubmed>41210694</pubmed><doi>10.7150/jca.119149</doi></cross_references></HashMap>